Faron Pharmaceuticals
Faron Pharmaceuticals developed an anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine is being tested in Phase III studies against COVID-19. Learn more
Launch date
Employees
Market cap
AUD438m
Enterprise valuation
AUD408m (Public information from Sep 2024)
Share price
£2.15568 FARN.L
Company register number 2068285-4
Turku Southwest Finland (HQ)
Authorizing premium user...